Homochlorcyclizine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C19H23ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N5MVC31W2N, chemically known as 1-(p-chloro-.alpha.-phenylbenzyl)hexahydro-4-methyl-1h-1, 4-diazepine, dihydrochloride but generally known as homochlorcyclizine, which bears US NIH Compound Identifier 3627. European Medicines Agency schedules Homochlorcyclizine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08050MIG. The term HOMOCHLORCYCLIZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). HOMOCHLORCYCLIZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule homochlorcyclizine under HS 29339940 and SITC 51577. As of Q4 2014, HOMOCHLORCYCLIZINE remains the US FDA Preferred Term for this commodity. Homochlorcyclizine bears US NLM identifiers UMLS ID C0163772 and NCI Concept Code C81142. SMILES: CLC1CCC(C(N2CCCN(CC2)C)C2CCCCC2)CC1.